Myung In Pharm to lead registration, commercialization and manufacturing of P2B001 in South Korea Myung In Pharm made a $5 million equity investment in Pharma Two B REHOVOT, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation of previously approved drugs for neurological … Read more
Rehovot, Israel – February 18, 2020 – Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced today the appointment of David S. Tierney M.D. as Chief Executive Officer, effective immediately as well as the establishment of a fully owned U.S. subsidiary to serve as the … Read more
Based on positive data from a Phase IIb pivotal study suggesting that P2B001 may offer effective therapy with minimal side effects for early stage Parkinson’s Disease (PD) patients, Pharma Two B initiated a multinational Phase III clinical trial Rehovot, Israel – February 6th, 2018 – Pharma Two B Ltd., a privately held company developing innovative … Read more
REHOVOTH, Israel, February 27, 2017 — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for Parkinson’s disease, announced today it has completed its third round of financing. The $30MM funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading … Read more
Rehovoth, Israel, June 30, 2015 — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company’s Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson’s Disease (PD). P2B001 is a combination of low dose pramipexole and low … Read more
Rehovoth, Israel, June 30, 2015 — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company’s Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson’s Disease (PD). P2B001 is a combination of low dose pramipexole and low … Read more
http://bit.ly/gS5LF5
